PeptSense
Create account

Peptide research

Semaglutide — compounding legality overview

Semaglutide is an approved GLP-1 receptor agonist (Ozempic, Wegovy). Compounding is heavily restricted when FDA-approved versions are available and shortage/discretion rules apply. Pharmacies and clinics track federal enforcement posture and state board positions closely.

GLP-1 compounding legality

Common names: Ozempic, Wegovy

PeptSense tracks Semaglutide across federal 503A Bulks List chain steps, PCAC advisory context, and state board positions. Status is never inferred from forums or marketing sites — only published citations with effective dates.

Federal 503A snapshot (illustrative)

Latest published federal event for 503A compounding pharmacies. Sign in for your licensed states and facility type.

Restricted
Summary
Honest curation baseline (2026-08-01): Semaglutide is a component of FDA-approved products. Compounding as an essentially copy of an approved drug is generally restricted under 503A when commercial product is available (shortage exceptions are fact-specific). Confirm shortage status and counsel. Not a legal determination.
Citation
FDA — essentially copies of approved drugs (503A)
Effective
Aug. 1, 2026

Not a legal determination. Replace placeholder citations during curation.

Run a full lookup

Get federal + state lanes, chain steps, printable answer cards, and compliance documents for the states you license in.

Create account View pricing

Related research topics

  • semaglutide compounding legality
  • can pharmacies compound semaglutide
  • semaglutide 503A status

← All peptides · Resources hub